5:24 PM
 | 
Jun 24, 2014
 |  BC Extra  |  Top Story

Vertex jumps on CF data

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) jumped $26.92 (40%) to $93.53 on Tuesday on positive data for two of the company's CF agents in a pair of Phase III trials -- a data readout that investors told BioCentury would be among the biggest make-or-break events of the quarter. In the identical TRANSPORT and TRAFFIC trials, Vertex's Kalydeco ivacaftor plus lumacaftor ( VX-809) met...

Read the full 298 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >